Objectives. To determine whether the 2014 Medicaid expansions facilitated by the Affordable Care Act affected overall and early-stage cancer diagnosis for nonelderly adults.
C
ancer is the second leading cause of death in the United States, behind only heart disease. 1 Early detection of cancer is associated with a higher probability of successful treatment, reduced mortality, and lower costs. 3 It is well established that the 2014 Medicaid expansions facilitated by the ACA improved coverage and access to care for nonelderly adults. 4 However, it is not yet known whether or how the expansions affected cancer diagnosis 5 ; this study fills that gap by using a quasi-experimental approach to compare changes in county-level diagnosis rates in states that expanded Medicaid with those that did not.
METHODS
We examined data from the 2010 to 2014 Surveillance, Epidemiology, and End Results (SEER) Program administered by the National Cancer Institute. SEER is a coordinated system of US cancer registries that collect comprehensive data on cancer cases reported in participating areas; it covers approximately 28% of the population and is considered nationally representative. 6 Of the 13 states participating in SEER, 9 expanded Medicaid by 2014 (California, Connecticut, Hawaii, Iowa, Kentucky, Michigan, New Mexico, New Jersey, and Washington), and 4 did not (Alaska, Georgia, Louisiana, and Utah). The data cover 611 counties. We restricted our study sample to firsttime cancer diagnoses for adults aged 19 to 64. We collapsed the data to the county-year level (n = 3055) and used county population estimates to calculate diagnosis rates for each county-year observation. We examined 3 county-level outcomes: total number of cancer diagnoses per 100 000 population, early-stage diagnoses per 100 000 population, and late-stage diagnoses per 100 000 population. Early-stage diagnoses are those that were in situ, local, or regional by direct extension only. Late-stage diagnoses are those that were regional with only lymph nodes involved, regional with lymph nodes involved and by direct extension, regional not otherwise specified, and distant. Unstaged diagnoses were included in total number of cancer diagnoses but not in the early-versus late-stage analysis. We estimated differencein-differences regression models to test whether diagnosis rates changed in states that expanded Medicaid relative to states that did not expand Medicaid. Our models controlled for other characteristics associated with access to care (including county unemployment rate, poverty rate, rurality, percentage of population that is non-White, percent nonelderly, and percent female), year fixed effects, and state fixed effects. We calculated SEs with the wild cluster bootstrap method.
The key identifying assumption in difference-in-differences analysis is that, in the absence of the intervention, diagnosis rates in the expansion and nonexpansion states would have followed similar trends; we tested this assumption using an event study. We also conducted falsification tests by estimating the same models for 2 populations whose eligibility for health insurance was unaffected by the Medicaid expansion: children younger than 18 years and adults older than 65 years. In addition, we repeated the main analysis with the sample stratified by age, tumor location, and whether the cancer type was amenable to screening. We used Stata version 14 (StataCorp LP, College Station, TX) to conduct all analyses. Figure 1 shows unconditional mean diagnosis rates for all 3 outcomes. According to our regression results (data not shown), Medicaid expansion was associated with a statistically significant increase in the overall diagnosis rate of 13.8 diagnoses per 100 000 population (95% confidence interval [CI] = 0.7, 26.9), which represents a 3.4% increase from pre-expansion levels (2010-2013 average for expansion counties). This was driven by an increase in the early-stage diagnosis rate, which increased 6.4% from pre-expansion levels (B = 15.4; 95% CI = 5.4, 25.3). Medicaid expansion had no significant effect on late-stage diagnoses.
RESULTS
As Figure 1 shows, the pre-expansion trends for overall and early-stage diagnoses were in the opposite direction of the difference-in-differences effect (i.e., states that eventually expanded Medicaid experienced a relative decrease in cancer diagnoses prior to expansion, in contrast to the relative increase in cancer diagnoses that they experienced after expansion). Moreover, our formal test of the parallel trends assumption failed to reject the null hypothesis of equal trends for expanding and nonexpanding states prior to the expansions (P > .11; Table A, available as a supplement to the online version of this article at http://www.ajph.org).
To investigate further whether preexisting trends or other unobserved factors may explain the effect of Medicaid expansion on overall and early-stage cancer diagnosis, we conducted falsification tests. We found no detectable effects of Medicaid expansion on the placebo groups of children and elderly for any of the 3 outcomes (Table B , available as a supplement to the online version of this article at http://www.ajph.org).
In our regressions stratified by age, tumor location, and whether the cancer was amenable to screening, we found that the increase in early-stage diagnoses was largely driven by increases among those aged 35 to 54 years and by cancers amenable to screening (Table C, available as a supplement to the online version of this article at http://www.ajph.org). The fact that the increase in early-stage diagnoses was concentrated in cancers amenable to screening is consistent with the increase resulting from the expansion of health insurance and access to care. The increase in overall diagnoses was largely driven by increases among those aged 45 to 54 and prostate cancer.
DISCUSSION
The 2014 Medicaid expansions increased overall cancer diagnosis by 3.4% and earlystage diagnosis by 6.4% in the first full year after expansion. This is consistent with other research that found that components of the ACA were associated with increased cancer diagnoses among those older than 65 years 7 and those younger than 26 years, 8, 9 as well as recent research from the National Cancer Database that indicated a shift to early-stage diagnosis for residents of Medicaid expansion states. 10 Expansion states had higher diagnosis rates even before 2014 (although the gap narrowed in the years preceding the expansion); the Medicaid expansion reversed this trend and widened disparities in cancer detection between expansion and nonexpansion states. 11 We cannot reject the null hypothesis that Medicaid expansions have no effect on the diagnosis of late-stage cancers. However, increases in health insurance coverage do lead to earlier detection, which raises the overall diagnosis rate.
Early cancer diagnosis is important for increasing the probability of successful treatment, reducing mortality, and controlling costs. 2 However, it is important to note that additional screening can result in falsepositive results, and the survival benefits of early detection have been overstated to some degree because of length-based sampling and lead-time bias. 12 Nevertheless, early detection is seen as a key step in reducing cancer mortality 2 and was a significant objective of the ACA. 3 Limitations of our analysis include the availability of only 1 year of post-2014 data and the participation of only 13 states. Although not all states participate in SEER, it remains the most comprehensive data source for studying cancer diagnosis in the geographic regions it covers. For example, the National Cancer Database is a hospital-based registry and may not be representative of the entire population within a state or region. 10 Our quasi-experimental Medicaid analysis is subject to potential time-varying confounders, although we found that preexpansion trends did not differ substantially between expansion and nonexpansion states.
Despite these limitations, this study provides new and important information about the benefits of Medicaid expansion for early cancer diagnoses.
PUBLIC HEALTH IMPLICATIONS
Cancer detection, particularly at an early stage, is a key public health priority in the United States. We have provided population-based evidence that the Medicaid expansions under the ACA led to more and earlier cancer detection in the working-age population. Our findings suggest that public health insurance may improve cancer detection, which is associated with better patient outcomes, including reduced mortality.
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